aTyr Pharma, Inc.
$ 0.52
-4.87%
02 Jun - close price
- Market Cap 53,595,000 USD
- Current Price $ 0.52
- High / Low $ 0.56 / 0.52
- Stock P/E N/A
- Book Value 0.59
- EPS -0.74
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.52 %
- ROE -1.06 %
- 52 Week High 7.29
- 52 Week Low 0.40
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$2.86
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-15 | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-13 | 2024-11-07 | 2024-08-13 | 2024-05-02 | 2024-03-14 | 2023-11-09 | 2023-08-09 |
| Reported EPS | -0.11 | -0.14 | -0.26 | -0.22 | -0.17 | -0.1809 | -0.2277 | -0.2256 | -0.23 | -0.25 | -0.2 | -0.22 |
| Estimated EPS | -0.1425 | -0.183 | -0.17 | -0.1845 | -0.19 | -0.226 | -0.22 | -0.24 | -0.24 | -0.24 | -0.2 | -0.28 |
| Surprise | 0.0325 | 0.043 | -0.09 | -0.0355 | 0.02 | 0.0451 | -0.0077 | 0.0144 | 0.01 | -0.01 | 0 | 0.06 |
| Surprise Percentage | 22.807% | 23.4973% | -52.9412% | -19.2412% | 10.5263% | 19.9558% | -3.5% | 6% | 4.1667% | -4.1667% | 0% | 21.4286% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATYR
2026-06-02 08:39:28
This article reports a significant decrease in the price target for aTyr Pharma (ATYR) shares. The new target is $6.48, representing a 37.13% reduction. Further details about the reasons for this change or the analyst responsible are not provided.
2026-06-01 19:39:28
aTyr Pharma is repositioning its lead drug, efzofitimod, for pulmonary sarcoidosis after its Phase 3 EFZO-FIT trial missed its primary endpoint (steroid dose reduction). Despite this, the drug showed positive results in steroid-free rates and quality of life. The company has received FDA feedback supporting a new Phase 3 trial (C-006) focusing on restrictive pulmonary sarcoidosis with forced vital capacity (FVC) as the primary endpoint.
2026-05-28 21:10:52
aTYR Pharma Inc. director Paul Schimmel recently purchased 100,000 shares of the company's common stock for $49,630, with the stock trading near its 52-week low. This insider buy increases his indirect holdings to over 779,000 shares through a trust and over 1.4 million shares directly. The purchase comes as investment analysis suggests ATYR is undervalued, with a fair value of $0.61, and the company prepares for a new Phase 3 study for its drug efzofitimod.
2026-05-28 20:10:52
A director at aTyr Pharma (NASDAQ: ATYR), Paul Schimmel, reported an open-market purchase of 100,000 shares of the company's common stock. The transaction occurred on May 27, 2026, at a weighted average price of $0.4963 per share, with individual trades ranging from $0.4907 to $0.50. These shares are held indirectly through entities associated with Schimmel, such as the Schimmel Revocable Trust and Paul Schimmel Prototype PSP.
2026-05-27 19:09:15
aTyr Pharma announced plans to submit an investigational new drug application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis. The company received feedback from the FDA, leading to a new trial design using forced vital capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire-Lung (KSQ-Lung) as the key secondary endpoint. The proposed global study will enroll approximately 372 patients and assess efzofitimod's efficacy and safety.
2026-05-21 03:38:50
Freedom Broker has upgraded its rating for ATyr Pharma from Hold to Buy. This change in rating suggests a more positive outlook on the company's stock from the brokerage firm.
